Home / Clinics Supported / Stem Cell Therapy
Open a Stem Cell Clinic. Massive Demand. One Hard Question.
The demand is already in your market. Often, the clinic is not. ACG plans yours with you, from product classification to opening day.
Book a Strategy CallNo medical background is required to own the business. An independent, state-licensed Medical Director directs all clinical care.
Stem Cell Clinic Demand: Where It Concentrates
Musculoskeletal is the largest application segment in the stem cell category (Coherent Market Insights, 2024), which is why joint programs are a common entry point for a new clinic.
Our wellness clinic launch program takes you from market review to opening day for one consulting fee, without the royalties of a stem cell clinic franchise.
The hard part is not opening. It is building a clinic that is still open, still compliant and still able to market itself three years from now.
Sources: Coherent Market Insights, 2024; Google’s cell and gene therapy ad policy; FDA, 2021.
What a Stem Cell Clinic Actually Offers Patients
How stem cell clinics are commonly structured. Not a statement of clinical outcomes: what any product does for a patient is for your Medical Director and the evidence to determine.
A common anchor service line for a new clinic.
Commonly built alongside PRP in the same treatment room.
A high-retention category that many operators pair with a cellular service line.
Frequently positioned inside a broader longevity practice with biomarker panels, hormone optimization, and IV therapy.
Prepared from and returned to the same patient in one procedure: a different regulatory posture than donor tissue, and where many clinics start. See how to open a stem cell clinic on that footing.
Imaging, lab panels, and structured intake and consent workflows. In a category under this much scrutiny, documentation is your defense.
The 361 vs 351 Question
Every Stem Cell Clinic Must Answer
Whether a stem cell clinic is legal depends first on how its products are classified. Under 21 CFR Part 1271, a product that meets every criterion in section 1271.10(a) is regulated solely under Section 361 of the Public Health Service Act and needs no premarket approval. Miss even one, and it is a Section 351 biological product that needs an approved license before it can be lawfully marketed.
Homologous use is where many products fail the test. A product must perform the same basic function in the recipient that it performed in the donor, and the criterion is mandatory. It is why FDA has issued warning letters to umbilical and birth-tissue suppliers whose products were marketed for uses it considers non-homologous, such as orthopedic conditions.
FDA's enforcement discretion for these products ended on May 31, 2021. Since then, anyone offering a product that needs premarket review without it does so at their own risk, and a provider may not administer an unapproved product without an approval or an investigational new drug application (IND) in effect.
This is the section many consultants skip. We lead with it, because the clinics that get it wrong do not get a second chance.
Before a lease is signed, ACG works through the 361 vs 351 question with you, your Medical Director, and your counsel. Every downstream decision depends on this answer.
Minimal manipulation. Homologous use. No combination with another article. No systemic effect or dependence on the metabolic activity of living cells, unless autologous or from a close blood relative. All four, not three.
ACG helps you press suppliers for the documentation that matters and recognize the answers that should end the conversation. A supplier's marketing claim is not a regulatory determination.
Intended-use claims help determine how a product is classified, so copy that promises what a product does for a condition can move it into a category that needs FDA approval.
A licensed physician reviews and approves protocols, product selection and patient consent before the first patient. ACG coordinates that relationship in all 50 states.
Stem Cell Clinic Consulting,
From Market to Opening Day
From product classification and supplier vetting to your Medical Director and launch marketing strategy, ACG plans each step with you before your first patient walks in.
Cash-Pay
No insurance billing, no reimbursement cycles, no margin erosion from third-party payers.
Required
An independent, state-licensed Medical Director directs all clinical care. You own and operate the business.
Launched
By our team, with 30+ years of combined experience. We help founders open in all 50 states.
Launch Window
From keys received, market and regulatory conditions permitting.
Questions About Opening
a Stem Cell Clinic
Direct answers on classification, suppliers, franchises and finding patients, including the uncomfortable ones. Anything else, ask on the strategy call.
View All FAQsWhat is the difference between a 361 and a 351 product?
Are umbilical or Wharton's jelly products automatically 361 compliant?
Do I need to be a physician to own a stem cell clinic?
Should I buy a stem cell clinic franchise or open my own?
Can my marketing copy affect how my product is regulated?
How does a stem cell clinic get new patients if Google and Meta restrict ads?
Open Your Stem Cell Clinic With the Team Behind Hundreds of Launches
Build it right, or do not build it. Talk with Grayson Miller about your market, the classification question and what opening takes. No pitch. No obligation.
- Local market review
- A product plan that holds up
- An honest read on fit
ACG is a consulting and advisory firm, not a medical practice; an independent, state-licensed Medical Director directs all clinical care. Results are not guarantees of income. Individual outcomes vary. The 60-day target begins from clinic keys received, market and regulatory conditions permitting.
Structured to keep you on the right side of the line.
Knowing the rules is the foundation of every clinic we help launch.
Your Medical Director Directs Care
You own and run the business. An independent, state-licensed Medical Director makes every clinical, prescribing and treatment decision, structured for your state's Corporate Practice of Medicine laws. We connect you to a vetted network; you retain your own provider.
We Know the Regulatory Lines
PRP, peptides, GLP-1 medications and cellular products each carry federal and state rules, and not every product or use is FDA-approved. Exosomes for therapeutic use are not FDA-approved at all, and we steer you away from them. Your menu and marketing are built to hold up to FDA, FTC and state medical board scrutiny.
No Hype. No Guarantees.
We show real ranges and never promise an income or a clinical outcome. What you earn depends on your market, your capital and your execution.
Altos Consulting Group is a business consulting and advisory firm, not a medical practice, and does not provide, prescribe or sell any drug, biologic, device or therapy. The FDA has stated there are currently no FDA-approved exosome products for the treatment of any disease; clinic owners are responsible for the compliance of every product, therapy and claim. See the full regulatory notice below.